Press Releases for JAZZ

Press Releases
Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
Jazz Pharmaceuticals to Announce Second Quarter Financial Results on August 11, 2009
Jazz Pharmaceuticals Completes $7 Million Private Placement
Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes
BenchmarkJournal.Com Free Analyst Review for RYAAY, LWSN, CNQR, XRAY, PLCM and JAZZ
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
Market Pulse Breaking News Alert for Tuesday, June 16, 2009: MNGA -- MagneGas Announces Agreement to Begin Commercial Sale of MagneGas(TM) Fuel As It Enters Into the $680 Million Metal Cutting Fuel Market!
Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
SmallCapSentinel.com Releases Market Actives List for JAZZ, MEXP, C, SAY, GOOG, AAPL
Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
Solvay's 1st Quarter 2009 Results
Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Jazz Pharmaceuticals Announces Issuance of Key Patent for Once-A-Day LUVOX CR(R)
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
Jazz Pharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
Jazz Pharmaceuticals, Inc. to Announce Third Quarter Financial Results on November 13, 2008
Jazz Pharmaceuticals to Present at Investor Conferences - Nov 4 2008 8:19AM
Jazz Pharmaceuticals to Present at Natixis Bleichroeder Hidden Gems Healthcare Conference
Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
Jazz Pharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Jazz Pharmaceuticals, Inc. to Announce Second Quarter Results on August 7, 2008
Jazz Pharmaceuticals Announces Closing of Registered Direct Offering
Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering
Jazz Pharmaceuticals Announces Development Timeline Updates
Jazz Pharmaceuticals Files Form S-3 Registration Statements
Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Jazz Pharmaceuticals to Present at Investor Conferences - May 27 2008 12:55AM
Jazz Pharmaceuticals to Present at Investor Conferences - Jun 3 2008 3:17AM
Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results - Jun 3 2008 3:16AM
Jazz Pharmaceuticals to Present at Citigroup Healthcare Forum - Jun 3 2008 3:15AM
Jazz Pharmaceuticals, Inc. Secures $75 Million Committed Equity Financing Facility - Jun 3 2008 3:14AM
Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008 - Jun 3 2008 3:14AM
Jazz Pharmaceuticals to Present at Morgan Stanley Conference
Jazz Pharmaceuticals' LUVOX CR Is Now Available for Patients With Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)